William Blair analyst Matt Phipps has maintained their bullish stance on AUTL stock, giving a Buy rating on October 20.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Matt Phipps has given his Buy rating due to a combination of factors including the promising data from Autolus Therapeutics’ Phase I CARLYSLE study. The study results demonstrated significant durability and deepening of responses in patients with severe refractory systemic lupus erythematosus (SLE), with a notable complete renal response in half of the patients treated. The safety profile of the treatment, obe-cel, was favorable, showing no instances of ICANS and only mild CRS, which is a positive indicator for its continued development.
Furthermore, the data revealed robust B-cell depletion and CAR-T cell expansion, suggesting a longer persistence compared to other therapies in the autoimmune setting. This promising efficacy and safety data supports the progression to a pivotal Phase II study, which is expected to start dosing by the end of 2025. The potential for accelerated approval based on positive Phase II results, followed by a Phase III trial, adds to the investment appeal, underpinning Phipps’s Buy rating for Autolus Therapeutics.
In another report released on October 20, Needham also maintained a Buy rating on the stock with a $10.00 price target.